Quotient Biodiagnostics, a global transfusion diagnostics group, Raised an additional $5.0m in equity funding.
Backers included Galen Partners and Paul Cowan, CEO and founding shareholder in Quotient.
The company intends to use the funding to continue development of its automation platform for transfusion diagnostics pursue its plans to build a new facility to facilitate the expansion of its existing liquid reagent business in Scotland (In conjunction with the funding, Quotient appointed Ed Farrell as the corporate President responsible for this project).
Based in the USA, Quotient Biodiagnostics, Inc. (the group’s North American sales and marketing business) provides the US blood banking community with transfusion diagnostics products manufactured over many years outside of the US. Alba Bioscience is the product development and manufacturing arm of Quotient.
FinSMEs
26/02/2013